This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback
Trial record 19 of 30 for:    Recruiting, Not yet recruiting, Available Studies | "Pheochromocytoma"

Adrenal Tumors - Pathogenesis and Therapy

This study is currently recruiting participants.
See Contacts and Locations
Verified October 2016 by Martin Fassnacht, University of Wuerzburg
Deutsche Krebshilfe e.V., Bonn (Germany)
German Federal Ministry of Education and Research
Information provided by (Responsible Party):
Martin Fassnacht, University of Wuerzburg Identifier:
First received: April 28, 2008
Last updated: October 28, 2016
Last verified: October 2016
The pathogenesis of adrenal tumors is still not fully elucidated and the treatment options for malignant tumors are poor. The current study investigates different aspects of the pathogenesis of adrenal tumors and evaluates different therapeutic options in patients with adrenocortical carcinoma.

Adrenal Tumors Adrenocortical Carcinoma Cushing Syndrome Conn Syndrome Pheochromocytoma

Study Type: Observational
Study Design: Observational Model: Case Control
Official Title: Investigation of the Tumorigenesis of Adrenal Tumors and Evaluation of New Therapeutic Options - Untersuchungen Zur Tumorgenese Von Nebennierentumoren Und Evaluation Neuer Therapieoptionen

Resource links provided by NLM:

Further study details as provided by Martin Fassnacht, University of Wuerzburg:

Biospecimen Retention:   Samples With DNA
Germline DNA Tumor samples Serum Plasma Urine

Estimated Enrollment: 500
Study Start Date: September 2002
Estimated Study Completion Date: December 2024
Estimated Primary Completion Date: December 2022 (Final data collection date for primary outcome measure)
Tumor material and corresponding biosamples from patients with adrenal tumors
control group
Biomaterial from patients without adrenal tumor


Ages Eligible for Study:   up to 100 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with adrenal tumors

Inclusion Criteria:

  • adrenal tumor detected by imaging

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00669266

Contact: Martin Fassnacht, MD 49-931-201-36507

University of Wuerzburg Recruiting
Wuerzburg, Germany, 97080
Contact: Martin Fassnacht, MD   
Contact: Stefanie Hahner, MD   
Principal Investigator: Martin Fassnacht, MD         
Sponsors and Collaborators
University of Wuerzburg
Deutsche Krebshilfe e.V., Bonn (Germany)
German Federal Ministry of Education and Research
Principal Investigator: Martin Fassnacht, MD U of Wuerzburg
  More Information

Responsible Party: Martin Fassnacht, Head of Endocrinology, University of Wuerzburg Identifier: NCT00669266     History of Changes
Other Study ID Numbers: Wue-Adrenal-Tumors-92/2002
Study First Received: April 28, 2008
Last Updated: October 28, 2016

Additional relevant MeSH terms:
Cushing Syndrome
Adrenocortical Carcinoma
Adrenal Gland Neoplasms
Pathologic Processes
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Adrenocortical Hyperfunction
Adrenal Gland Diseases
Endocrine System Diseases
Neoplasms, Glandular and Epithelial
Adrenal Cortex Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Adrenal Cortex Diseases
Epinephryl borate
Adrenergic alpha-Agonists
Adrenergic Agonists processed this record on August 16, 2017